Trials / Completed
CompletedNCT00770783
Magnetic Seizure Therapy (MST) for Treatment Resistant Major Depression
Efficacy of Magnetic Seizure Therapy (MST) in Refractory Major Depression
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- University Hospital, Bonn · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The investigators intend to test in a single center, clinical pilot efficacy study the primary hypothesis that Magnetic Seizure Therapy (MST) as add-on therapy to a controlled pharmacotherapy is efficacious in the treatment of refractory major depression assessed with the Hamilton Depression Rating Scale (HAMD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Thymatron | Right unilateral placement, 3x seizure threshold, 3 times per week for 4 weeks |
| DEVICE | Tonica MagPro MST | 100% power, vertex placement, 3 times per week for 4 weeks |
Timeline
- Start date
- 2005-02-01
- Primary completion
- 2013-09-01
- Completion
- 2014-05-01
- First posted
- 2008-10-10
- Last updated
- 2018-08-06
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00770783. Inclusion in this directory is not an endorsement.